Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Slides:



Advertisements
Similar presentations
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
A Practical Guide to the Prevention of Surgical Adhesions
Atrial Fibrillation and PCI
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Up to Date on Which NOAC for Which Patient
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Through Thick and Thin.
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
Oral Anticoagulation in AF
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Taking the "Cryptogenic" Out of Cryptogenic Stroke
NOACs in AF: Consequences of Underdosing and NonAdherence
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
What You Didn't Know About AF and Renal Dysfunction
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in AF: Consequences of Underdosing and NonAdherence
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Figure 8. Stroke prevention strategy in patients with AF
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Burden of Atrial Fibrillation

The Percentage of Strokes Attributable to AF Increases With Age

Unmet Needs in Managing Elderly With AF

Issues of OAC in the Elderly

Efficacy and Safety of NOACs Pre-specified Meta-analysis of all 71,683 Patients

Efficacy vs Safety NOAC 4-trial Meta-analysis Full Dose

Ethnic Differences in Rate of ICH

NOAC Antidotes in Clinical Trials

NOAC Dose Reduction

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.